A Diabetes Breakthrough: New Drug to Delay the Onset of Clinical Disease

Type 1 diabetes (T1D) affects approximately one in every 300 individuals under 20 years old. Although insulin remains the cornerstone for T1D treatment, it doesn't alter the underlying autoimmune condition. Even with advances like more physiological insulin analogs, continuous glucose monitoring and automated insulin delivery systems, the majority of those with T1D fail to meet therapeutic targets tied to a reduced long-term risk of complications. The management of T1D can be costly, complex and emotionally draining for both patients and their families. New methods that change the natural course of T1D, instead of merely treating hypoglycemia, could significantly improve both quality of life and health outcomes. 

Listen to our pediatric expert discuss advancements in diabetes management

In this episode, our expert discusses:

• How the predictability of T1D has changed over the years 
• Accessibility and expansion of screening programs worldwide 
• Stages of T1D 
• Screening and intervention timelines 
• New breakthrough medication, a monoclonal antibody, approved in the U.S. to delay the onset of clinical T1D 

Pediatric endocrinology at Children's Colorado

At Children's Colorado, we're committed to helping all healthcare professionals improve the quality of life for children with endocrine disorders. Get the latest in pediatric endocrinology information to better your practice and learn about innovation within our various programs.